Comparative properties of feline immunodeficiency virus (FIV) and human immunodeficiency virus type 1 (HIV-1) proteinases prepared by total chemical synthesis

被引:24
作者
Schnolzer, M
Rackwitz, HR
Gustchina, A
Laco, GS
Wlodawer, A
Elder, JH
Kent, SBH
机构
[1] Scripps Res Inst, DEPT MOL BIOL, LA JOLLA, CA 92037 USA
[2] NCI, FREDERICK CANC RES & DEV CTR, ABL BASIC RES PROGRAM, MACROMOL STRUCT LAB, FREDERICK, MD 21702 USA
[3] Scripps Res Inst, DEPT CELL BIOL, LA JOLLA, CA 92037 USA
[4] GERMAN CANC RES CTR, DIV CELL BIOL 0110, D-69120 HEIDELBERG, GERMANY
关键词
D O I
10.1006/viro.1996.0528
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The aspartyl proteinase (PR) encoded by the feline immunodeficiency virus (FIV) was prepared by total chemical synthesis. The 116-amino-acid polypeptide chain was assembled in a stepwise fashion using a Boc chemistry solid-phase peptide synthesis approach and subsequently folded into the biologically active dimeric proteinase. The synthetic enzyme showed proteolytic activity against a variety of different peptide substrates corresponding to putative cleavage sites of the Gag and Gag-Pol polyproteins of FIV. A comparative study with the proteinase of human immunodeficiency virus type 1 (HIV-1) showed that the FIV and HIV-1 enzymes have related but distinct substrate specificities. In particular, HIV-1 PR and FIV PR each show a strong preference for their own MA/CA substrates, despite identical amino acid residues at four of seven positions from P3-P4' of the substrate including an identical MA/CA cleavage site (between Tyr similar to Pro residues), FIV PR also showed a requirement for a longer peptide substrate than HIV-1 PR. Defining the similarities and the differences in the properties of these two retroviral enzymes will have a significant impact on structure-based drug design. (C) 1996 Academic Press, Inc.
引用
收藏
页码:268 / 275
页数:8
相关论文
共 38 条
[11]   HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .2. USE OF PH RATE STUDIES AND SOLVENT KINETIC ISOTOPE EFFECTS TO ELUCIDATE DETAILS OF CHEMICAL MECHANISM [J].
HYLAND, LJ ;
TOMASZEK, TA ;
MEEK, TD .
BIOCHEMISTRY, 1991, 30 (34) :8454-8463
[12]   HUMAN IMMUNODEFICIENCY VIRUS-1 PROTEASE .1. INITIAL VELOCITY STUDIES AND KINETIC CHARACTERIZATION OF REACTION INTERMEDIATES BY O-18 ISOTOPE EXCHANGE [J].
HYLAND, LJ ;
TOMASZEK, TA ;
ROBERTS, GD ;
CARR, SA ;
MAGAARD, VW ;
BRYAN, HL ;
FAKHOURY, SA ;
MOORE, ML ;
MINNICH, MD ;
CULP, JS ;
DESJARLAIS, RL ;
MEEK, TD .
BIOCHEMISTRY, 1991, 30 (34) :8441-8453
[13]  
IDO E, 1991, J BIOL CHEM, V266, P24359
[14]  
ISHIDA T, 1989, J AM VET MED ASSOC, V194, P221
[15]   MURINE LEUKEMIA-VIRUS MATURATION - PROTEASE REGION REQUIRED FOR CONVERSION FROM IMMATURE TO MATURE CORE FORM AND FOR VIRUS INFECTIVITY [J].
KATOH, I ;
YOSHINAKA, Y ;
REIN, A ;
SHIBUYA, M ;
ODAKA, T ;
OROSZLAN, S .
VIROLOGY, 1985, 145 (02) :280-292
[16]   ACTIVE HUMAN IMMUNODEFICIENCY VIRUS PROTEASE IS REQUIRED FOR VIRAL INFECTIVITY [J].
KOHL, NE ;
EMINI, EA ;
SCHLEIF, WA ;
DAVIS, LJ ;
HEIMBACH, JC ;
DIXON, RAF ;
SCOLNICK, EM ;
SIGAL, IS .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1988, 85 (13) :4686-4690
[17]   HTLV-III GAG PROTEIN IS PROCESSED IN YEAST-CELLS BY THE VIRUS POL-PROTEASE [J].
KRAMER, RA ;
SCHABER, MD ;
SKALKA, AM ;
GANGULY, K ;
WONGSTAAL, F ;
REDDY, EP .
SCIENCE, 1986, 231 (4745) :1580-1584
[18]   STRUCTURE OF COMPLEX OF SYNTHETIC HIV-1 PROTEASE WITH A SUBSTRATE-BASED INHIBITOR AT 2.3-A RESOLUTION [J].
MILLER, M ;
SCHNEIDER, J ;
SATHYANARAYANA, BK ;
TOTH, MV ;
MARSHALL, GR ;
CLAWSON, L ;
SELK, L ;
KENT, SBH ;
WLODAWER, A .
SCIENCE, 1989, 246 (4934) :1149-1152
[19]   CRYSTAL-STRUCTURE OF A RETROVIRAL PROTEASE PROVES RELATIONSHIP TO ASPARTIC PROTEASE FAMILY [J].
MILLER, M ;
JASKOLSKI, M ;
RAO, JKM ;
LEIS, J ;
WLODAWER, A .
NATURE, 1989, 337 (6207) :576-579
[20]   MOLECULAR TARGETS FOR AIDS THERAPY [J].
MITSUYA, H ;
YARCHOAN, R ;
BRODER, S .
SCIENCE, 1990, 249 (4976) :1533-1544